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Cell therapy with polyclonal regulatory T cells (Tregs) has been translated into the
clinic and is currently being tested in transplant recipients and patients suffering from
autoimmune diseases. Moreover, building on animal models, it has been widely reported
that antigen-specific Tregs are functionally superior to polyclonal Tregs. Among various
options to confer target specificity to Tregs, genetic engineering is a particularly timely
one as has been demonstrated in the treatment of hematological malignancies where
it is in routine clinical use. Genetic engineering can be exploited to express chimeric
antigen receptors (CAR) in Tregs, and this has been successfully demonstrated to be
robust in preclinical studies across various animal disease models. However, there are
several caveats and a number of strategies should be considered to further improve on
targeting, efficacy and to understand the in vivo distribution and fate of CAR-Tregs. Here,
we review the differing approaches to confer antigen specificity to Tregs with emphasis
on CAR-Tregs. This includes an overview and discussion of the various approaches to
improve CAR-Treg specificity and therapeutic efficacy as well as addressing potential
safety concerns. We also discuss different imaging approaches to understand the
in vivo biodistribution of administered Tregs. Preclinical research as well as suitability of
methodologies for clinical translation are discussed.
Keywords: Tregs (regulatory T cells), transplantation, CAR (chimeric antigen receptor), cell therapy, autoimmunity,
regulatory, antigen specific
INTRODUCTION
Regulatory T cells (Tregs) are a subset of T cells that function to maintain homeostasis and prevent
autoimmunity (1). Tregs make up 5–10% of the CD4+ T cell population (2) and are characterized
by co-expression of CD4, CD25, the transcription factor Forkhead box protein 3 (FOXP3) and
low levels of CD127. Although conventional human T cells (Tconv) can transiently express
FOXP3, high FOXP3 levels and demethylation of the Treg specific demethylated region (TSDR),
a conserved region within the FOXP3 gene, are distinct features of Tregs (3). The importance of
FOXP3 in Tregs is supported by the evidence that mutations in the FOXP3 locus lead to Treg
dysfunction and severe autoimmunity, as was first identified in Scurfy mutant mice (4) and the
immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX) in humans (5).
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Tregs are divided in thymus-derived (tTregs) and peripheral-
derived Tregs (pTregs) (6). During T cell development, those
naïve CD4+ T cells receiving an intermediate TCR signal are
driven to differentiate into Tregs—the quantitative difference
in strength of such signal is thought to determine Tconv cell
or Treg lineage commitment (7). Peripheral Tregs develop
when FOXP3− Tconv encounter repeated stimulation to non-self
antigens or receive inadequate co-stimulation, as well as exposure
to IL-10 and TGF-β (8).
Tregs suppress the immune system by different mechanisms
including contact-dependent mechanisms, through CTLA-4
engagement for example, and contact-independent, such as the
release of cytokines e.g., IL-35 or IL-10 [reviewed in (9)]. Given
their proven role in preventing autoimmune diseases, Tregs
have obvious potential in the promotion of tolerance. Although
human Tregs constitute a small proportion of circulating CD4+
T cells, they are attractive candidates for immunotherapeutic
purposes given that they can be isolated, manipulated and
expanded in large numbers in vitro. Tregs can be applied in
the treatment of autoimmune diseases and in the prevention of
transplant rejection and graft vs. host disease (GvHD).
ADOPTIVE TREG THERAPY: FROM
POLYCLONAL TO ANTIGEN SPECIFIC
The first phase I clinical trials investigating the safety of
adoptive transfer of Tregs were in the treatment of bone
marrow patients to prevent GvHD,NCT00602693 (10–12). These
trials demonstrated the safety and efficacy of Treg therapy.
Autologous polyclonal Tregs have been infused in patients with
type 1 diabetes (T1D) as well, demonstrating again the safety
and feasibility of adoptive Treg therapy in this disease setting
[ISRCTN06128462, (13) and NCT02691247, (14)]. Treg therapy
has reached the organ transplant arena as well (UMIN-000015789
and NCT02088931) (15, 16). We have demonstrated the safety of
adoptively transferred Tregs in two phase I clinical trials in liver
(ThRIL, NCT02166177) and kidney (ONE study, NCT02129881)
transplant patients (17, 18).
However, whilst the above clinical studies have shown the
potential of polyclonally expanded Tregs, we and others have
demonstrated the superiority of antigen-specific Tregs compared
to polyclonal Tregs in animal models. Tang et al. successfully
isolated and expanded Tregs from a transgenic mouse expressing
a TCR specific for an islet antigen, and showed that antigen-
specific Tregs prevented and even reversed diabetes in non-
obese diabetic mice (19, 20). More recently, human Tregs were
modified in vitro to generate Tregs specific for donor antigens,
by co-culturing Tregs with donor-derived dendritic cells (DCs)
or B cells (21, 22). The superiority of donor-specific human
Tregs compared to polyclonal Tregs was demonstrated in vitro
and in vivo in a humanized mouse model of human skin
transplant (21, 22). Similar results were obtained in vitro by
Zheng et al. as they demonstrated that mature B cells were better
stimulants than immature DCs in generating Tregs expressing
higher levels of FOXP3 and CD25, and with superior suppressive
capacity (23). Already as part of the ONE Study (NCT02129881)
kidney transplant patients have been treated with donor-specific
Tregs and additional clinical trials in transplant patients are
investigating the use of donor-reactive Tregs [reviewed by (9)].
Evolving from the use of APCs to generate Tregs with
specificity for the target antigen, research has shifted toward gene
transfer. Wright et al. transduced Tregs with a TCR specific for
ovalbumin (OVA) and restricted by the MHC-class II Ab. These
Tregs transferred in vivo were able to inhibit a well-established
antigen induced arthritis in which mice were immunized with
methylated BSA (mBSA) followed by intra-articular knee re-
challenge with mBSA to induce T cell-mediated tissue damage.
The OVA-specific Tregs were able to decrease inflammation to
the knee but only when OVA was present (24). In the same study
a similar effect was obtained with CD4+ Tconv transduced with
the same TCR and FOXP3; engineering CD4+ Tconvs to express
FOXP3 endows them with a suppressive function (24). We
generated Tregs from C56BL/6 recipient mice specific for donor
BALB/c antigen by retroviral transduction of a TCR specific for a
peptide derived from MHC-class I Kd and presented by MHC-
class II Ab. We demonstrated that Tregs with this specificity
contributed to the indefinite survival of BALB/c heart transplants
into B6 (25). Brusko et al. transduced human Tregs with a TCR
specific for the melanoma antigen tyrosinase and restricted by
HLA-A∗0201. Tregs were expanded in vitro and administered
in vivo in a tumor model. They were able to inhibit effector
T cells leading to tumor growth (26). Hull et al. transduced
Tregs with two TCRs isolated from islet-specific and influenza-
specific CD4+ T cell clones. The authors showed that the
ability of the islet antigen-specific TCRs to induce Treg mediate
antigen-specific suppression in vitrowas significantly lower when
compared to what was achieved using TCRs with specificity for
viral antigens (27). More recently, Kim et al. transduced Tregs
with a TCR specific for myelin basic protein (MBP) isolated from
a T cell clone derived from amultiple sclerosis patient (28). These
Tregs suppressedMBP-specific T effector in vitro and in vivo they
ameliorated experimental autoimmune encephalitis (EAE) (28).
As an alternative to the use of Tregs as cell therapy,
several studies have looked at generating Tregs by manipulating
CD4+ Tconv cells to express FOXP3. In hemophilia, up
to one third of patients receiving therapeutic factor VIII
(FVIII) infusions develop neutralizing antibodies. Herzog et al.
transduced CD4+ Tconv with FOXP3 and FVIII. Following
administration of these cells to hemophilia Amice, the formation
of neutralizing antibodies to FVIII was suppressed (29). In an
animal model of type 1 diabetes, Jaeckel et al. transduced islet-
specific CD4+ Tconv with FOXP3. These cells were activated
in the pancreatic lymph nodes and reversed recent-onset
diabetes (30). Beavis et al. showed that the ectopic expression
of FOXP3 in pathogenic synovial T cells from rheumatoid
arthritis patients attenuated their function (31). Loser et al.
showed the efficacy of FOXP3-transduced Tconv in suppressing
contact hypersensitivity responses in mice. Moreover, these cells
diminished autoimmune dermatitis in CD40L transgenic mice
and cleared antinuclear antibodies (32). These studies are seminal
demonstrating the acquisition by Tconvs of a suppressive profile,
equally research within immunoregulation has lately been more
focused toward enhancing Tregs for cell therapy.
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An alternative method to confer specificity to Tregs is by
transducing these cells with chimeric antigen receptors (CAR).
CAR technology offers some advantages over TCR engineering.
These include bypassing HLA restriction upon activation of
T cells expressing CARs, increased specificity through the
requirement of co-receptor signaling, and the targeting flexibility
of CARs (any soluble or surface multivalent antigen can serve as
target). In the following sections we focus on CARs to enhance
Treg therapy.
CHIMERIC ANTIGEN RECEPTORS:
LESSONS FROM CANCER THERAPY
CARs have been developed and by now clinically implemented
in oncology to treat certain cancers. They represent an approach
to fine-tune adoptively transferred therapeutic T cells to target
specific antigens by-passing MHC-restriction and thereby enable
these therapeutic cells to attack the cancer. CARs are artifical
molecules engineered into target cells. They are composed of
an extracellular target-recognition domain (e.g., a scFv specific
for the target antigen), hinge and transmembrane domains, and
intracellular signaling domains to propagate activation signals
as a consequence of extracellular target engagement. CARs are
less sensitive in response than TCRs due in part to the number
of molecules involved in the TCR machinery, i.e., CD4/CD8
co-receptors, immunoreceptor tyrosinase-rich activation motifs
(ITAMs), and subunits within the receptor complex (CARs
require 100–10,000 molecules per target cell while TCRs need
<10 molecules per target cell) but bind with higher affinity than
the TCR; although studies have investigated increasing CAR
sensitivity by incorporating lower affinity single-chain variable
fragment [scFv; (33, 34)].
From CAR-T Cells in Oncology to
CAR-Tregs
The first CAR was composed of a CD3ζ chain of the TCR/CD3ζ
complex, but T cell activation was neither persistent in vivo,
nor sustained and the T cells did not proliferate sufficiently (35,
36). Second generation CARs contain an additional intracellular
feature, a co-stimulatory domain, which has the purpose to
potentiate the signaling response of the CAR. Several co-
stimulatory domains including those fromCD28, 4-1BB (CD137)
and OX40 (CD134) molecules have been explored in CAR-
T cell therapy. Third generation CARs are composed of
two different co-stimulatory molecules. Indeed it were second
generation CARs that led to the breakthrough in cell-based
cancer immunotherapy. In 2017, the FDA approved the first
clinical products, tisagenlecleucel and axicabtagene ciloleucel—
trademarked as Kymriah R© and Yescarta—which are autologous
CD19b-targeted CAR-T-cell immunotherapies for the treatment
of B-cell acute lymphoblastic leukemia and B-cell lymphoma,
respectively (37–39). CAR-T immunotherapies have the potential
to be curative, but so far not all patients have responded
and sometimes the effects were only temporary (39–41).
CAR-T cell therapy has been also associated with severe/life-
threatening side-effects and fatalities during clinical trials (42,
43). Research into CARs specific for tumor-related antigens in
hematological malignancies paved the way for the application
of CARs in immunoregulation. CAR-T cells have been already
applied to treat autoimmune disease. In an animal model of
pemphigus vulgaris, which is a rare severe autoimmune disease
in which blisters of varying sizes break out on the skin and
mucous membranes, chimeric auto-antibody receptor (CAAR)-
T cells were generated with specificity for the keratinocyte
adhesion protein Dsg3 (44). The CAAR-T cells exhibited specific
cytotoxicity to anti-Dsg B cells in vivo without off-target toxicity
(44). Although engineering CAAR-T cells may be effective
in inhibiting some autoimmune diseases, Tregs can also be
applied due to their powerful immunosuppressive and tolerance-
promoting properties.
Tregs have been transduced to express CARs and tested in
pre-clinical models of autoimmunity, GvHD and transplantation
as well as colitis. Elinav et al. generated a transgenic mouse
whose T cells including the Tregs expressed a CAR specific
for 2,4,6-trinitrophenol. The adoptive transfer of CAR-Tregs
to wild-type mice suffering 2,4,6-trinitrobenzenesulfonic acid-
induced colitis was associated with significant amelioration of
colitis and improved survival (45). The same group generated
Tregs expressing a CAR specific for the human carcinoembryonic
antigen (CEA). These Tregs markedly suppressed the severity
of colitis in the CEA transgenic mouse, CEABAC, where colitis
was induced by transfer of effector T cells specific for CEA (46).
Another study used a CEA transgenic mouse to show that CEA-
specific CAR-Tregs can inhibit allergic airway inflammation (47).
More recently, Tenspolde et al. generated CAR-Tregs specific
for insulin but despite them proliferating in response to insulin
and being suppressive in vitro, these CAR-Tregs did not prevent
spontaenous diabetes in mice; interestingly these cells persisted
up to 4 months post adoptive transfer (48). Furthermore, in
a mouse model of hemophilia A, Zhang et al. created Tregs
expressing a B cell-targeting antibody receptor (BAR) containing
the immunodominant FVIII C2 or A2 domains. The BAR-Tregs
completely prevented anti-FVIII antibody development in FVIII-
immunized mice. They also demonstrated a direct effect on
FVIII-specific B cells (49).
In transplantation, we and others have generated Tregs
expressing an HLA-A2-specific CAR (A2-CAR-Tregs) (50–
52). We have shown that A2-CAR-Tregs were functionally
superior compared to polyclonal Tregs in vitro and in vivo
in a humanized mouse model of BRG mice bearing a human
skin transplant reconstituted with 5:1 PBMCs to CAR-Tregs,
assessed by histological analysis 5 weeks post adoptive transfer
(51). Noyan et al. also demonstrated the efficacy of an A2-
CAR-Tregs in inducing indefinite survival of allogeneic human
skin transplants in a humanized mouse model of NRG mice
injected intraperitoneally with 7.5:1 PBMCs to A2-CAR-Tregs
and graft survival was assessed (52). Similar A2+CAR-Tregs
were also shown to ameliorate xenogeneic GvHD (50). Lately,
the Levings group produced a panel of humanized HLA-A2
CAR-Tregs and developed a method to map the specificity
of CARs, showing that humanization reduced HLA-A cross-
reactivity (53). Recently, the same group also investigated the
ability of murine HLA-A2 CAR-Tregs to prevent allograft
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rejection in immunocompetent mice (54). The results showed
that these Tregs prolonged skin allograft survival and humural
alloresponses but not in presensitised mice, suggesting HLA-
A2 CAR-Tregs are unable to inhibit memory T or B cell
responses (54).
In the following sections we review the challenges for CAR-
Treg therapy and discuss ways to improve CAR-Treg function,
safety and specificity for clinical applications.
CAR Co-stimulatory Endodomain
Functions in T Cells
Past studies have focused on optimizing the CAR co-stimulatory
endodomain design to provide robust CAR-T cells for fighting
cancer (55) of which a wide variety had been tested. For
example, CAR co-stimulatory endodomains tested in T cells
in addition to CD28 include 4-1BB, OX40, inducible T cell
co-stimulator (ICOS) and CD27. Zhang et al. reported that
4-1BB co-stimulation plays an important role for memory
CD8+ T cell proliferation ex vivo and is superior to CD28 co-
stimulation in terms of generating antigen-specific CD8+ T cell
(56). Transduction of CD4+ (57) and of a mixture of CD4+ and
CD8+ (1:1 ratio) (58) T cells with a CAR construct incorporating
4-1BB resulted in augmented T cell longevity. This was due to 4-
1BB co-stimulation via the CAR decreasing the exhaustion rate
of T cells induced by tonic CAR signaling (57). In another study,
Li et al. showed that CAR CD4+ and CD8+ T cells with 4-1BB
co-stimulatory endodomain improved T cell function via the NF-
κB signaling pathway. Compared to the CD28 co-stimulatory
domain, 4-1BB was more associated with the upregulation of
anti-apoptotic proteins, which might explain their function in
prolonging T cell longevity (59). Whilst OX40 activity enhanced
CD4+ and CD8+ T cell expansion and survival, it also blocked
thymic CD4+ Treg activity and antagonized the generation
of inducible CD4+ Tregs (60–62). However, OX40 activity
upregulated anti-apoptotic Bcl-2 family members including Bcl-
xL, Bcl-2 and Bfl-l and molecules involved in the cell cycle
such as survivin and aurora B kinase (63–65). Additionally,
Hombach et al. found that CD4+ T cells transduced with a CAR
containing anOX40 endodomain abrogated IL-10 secretion, even
in conjunction with a CD28 co-stimulation domain, without
impairing the other Teff functions, tipping the balance against
suppression in cancer (66). Prior to that, the authors investigated
the effect of OX40, 4-1BB, and CD28 CAR endodomains in
CD4+ and CD8+ T cells, and determined that CD28 was the
most potent at initiating a T cell response, and OX40 and 4-
1BB sustained the response with OX40 outperforming the other
two for the most prolonged time (67). Another co-stimulatory
molecule expressed by T cells is ICOS, which is essential for
T cell activation and proliferation (68). ICOS has a significant
homology to CD28 and CTLA-4 (69, 70) but is not constitutively
expressed on resting T cells but upregulated upon TCR and/or
CD28 engagement (69, 71). Guedan et al. demonstrated that
ICOS expression via CAR CD4+ and CD8+ T cells enhanced
anti-tumor activity and promoted cell survival longer than 4-1BB
or CD28 CAR-T cells (72). CD27 is essential for CD4+ T cell
functions such as promoting antigen-specific cell expansion of
naïve T cells and the generation of memory T cells (73). CD27 co-
stimulation via CAR CD4+ and CD8+ T cells upregulates anti-
apoptotic Bcl-XL protein expression and resistance to antigen-
induced apoptosis, leading to increased numerical expansion
although it underwent equal cell division without CD27 (CD3ζ
alone). CD27 CAR-T cells may be better than CD28 CAR-T cells
due to enhanced survival and accumulation thus quantitatively
increased response (74).
However, whether expression of these co-stimulatory
endodomains via CARs on Tregs enhances their function in
a similar manner to those found in CAR-T cells is still to
be elucidated.
CLINICAL PRODUCTS OF CAR-T
Engineering CAR-Tregs destined for the clinic involves different
stages in the GMP facility that need to be optimized. Currently,
GMP protocols rely on either magnetic isolation of total
CD4+CD25+ Treg populations, or fluorescence-activated cell
sorted (FACS) (75). It is advisable that for the generation of CAR-
Tregs the Tregs need to be highly pure to avoid any expansion of
“contaminating” Teff. Delivering the CAR to the Tregs involves
viral-based transfer (i.e., lentivirus or retrovirus) and although
to date no safety concerns have been reported with genetically
engineered T cells, using non-viral vehicles have been gaining
traction, such as transposon/transposases (i.e., Sleeping beauty,
piggyBac transposon) or gene-editing tools which will also be
discussed (76). With respect to expansion, protocols already
developed for polyclonal Treg infusion can be employed for
CAR-Tregs. Alternatively, semi-automatic systems employed in
CAR-T cell development such as rocking-motion bioreactors and
static culture bags can be optimized for CAR-Treg expansion
(77). The number of Tregs needed for therapy remains unclear
and the doses of administered Tregs varied in different trials. We
have injected polyclonal Tregs ranging from 105 to 107 cells/kg
bodyweight in the ThRIL and the ONE Studies (17, 18) The
prediction is that fewer numbers of CAR-Tregs would be needed,
although solid organ transplant trials employing antigen-specific
Tregs have ranged up to 9 × 108 cells [for more details please
refer to (9)].
ENHANCING CAR-TREGS
Engineering CAR-Tregs for clinical applications include boosting
their potency, persistence, and safety. Given that CARs are
composed of building blocks, modifying the scFv targeting
moiety, or the intracellular co-stimulatory signaling domain has
been a focus, and will be discussed herein. Additional payloads to
the construct such as including safety switches or in vivo tracking
modalities like imaging tracers are also discussed.
Like conventional T cells, Tregs express an array of
different stimulatory and inhibitory receptors (78). However,
the function of each of these receptors in Tregs may be
different compared to conventional T cells. Due to the
various properties of different co-stimulatory molecules, it is
unlikely that one particular co-stimulatory molecule can serve
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all therapeutically required purposes for CAR-Treg therapy.
Therefore, it is likely that for optimal function and persistence
of therapeutic CAR-Tregs will be different, perhaps simultaneous
co-stimulation signals are required, and possibly at different
time points.
Optimizing CAR-Tregs for Universal
Recognition and Function
Most of the available studies in pre-clinical models of diseases
have been focusing on mono-specific CAR-Tregs. Increasing
the specificity of CAR-Tregs could boost their therapeutic
efficacy, coined with the added advantage of Tregs functioning
indirectly through bystander suppression. Different methods of
implementing universal recognition of CAR-Tregs are reviewed.
The first option is to infuse a pool of CAR-Tregs with
different specificities (Figure 1A). This has been tested by pooling
monospecific CAR-T cells targeting CD19/CD123 for B-ALL and
human epidermal growth factor receptor-2 (HER2)/IL-13Rα2 for
glioblastoma (79–81). However, this is logistically challenging,
as expansion of autologous CAR-Tregs specific for different
target antigens would be limited by the number of autologous
Tregs available and the high numbers of antigens to target.
Therefore, combinatorial antigen strategies or dual CAR-T cells
have been developed (Figure 1B) using cells transduced with two
different CARs with different antigen specificities and signaling
domains (79, 80, 82, 83). The dual CAR-T cells were more
efficient than pooled CAR-T cells in preventing antigen escape
and demonstrated increased anti-tumor efficacy (79). Bi-specific
CARs (or Tandem CAR) targeting two different antigens can
also be used (Figure 1C) (81, 84, 85), but limitations include
mouse scFv immunogenicity, the cross-pairing of the variable
light and heavy chains between different scFvs and limited viral
vector package size (86). Developing a modular or universal
CAR (UniCAR; Figure 1D) where the CAR utilizes a soluble
connecting molecule to engage the antigen of interest is also
another strategy (87). Cells of interest are indirectly connected
to the UniCAR through a distinct targeting module, called CAR-
adaptors [cf. (88)]. Therefore, a tailored control of the Treg
activity is possible, as the activation of the UniCAR-Tregs is
strictly dependent of the targeting module and changing the
targeting module opens to universal applications. Koristka et al.
showed that Tregs derived from patients with autoimmune
conditions were successfully engineered with UniCARs with
4-1BB/CD3ζ intracellular domains and these UniCAR-Tregs
were able to suppress patient-derived effector cell functions,
as determined by luciferase-expressing PC3-PSCA cancer cells
(87). A FITC-CAR-Treg has been described by Pierini et al.,
which allows the combination of any monoclonal antibody to
the FITC-CAR, facilitating a customisable approach to targeting
antigens. The efficacy of the FITC-CAR-Tregs was demonstrated
by showing that the injection of H-2Dd-mAbCAR-Tregs into B6
mice increased the survival of BALB/c skin and islet allograft as
compared to isotype-mAbCAR-Tregs (89). These last approaches
are quite promising and it is the first step toward off-the shelf
therapies, which could help improving the deliverability and cost
associated with these treatments.
CAR Co-stimulatory Endodomain Function
in Tregs
Different co-stimulatory molecules provide different functions.
Thus, it is unlikely that one particular co-stimulatory molecule
can serve all therapeutic purposes required for CAR-Treg
therapy. Therefore, it is likely that for optimal function
and persistence of therapeutic CAR-Tregs, a particular co-
stimulatory endodomain is chosen and used for the disease
or health indication context that best benefits from this co-
stimulatory endodomain. In addition, perhaps a combination
of co-stimulation signals are required, and possibly at different
time points to achieve a robust or efficient CAR-Treg therapy
for patients.
The importance of the CD28 co-stimulatory domain in CAR-
Tregs has been demonstrated by various groups. MacDonald
et al. demonstrated that alloantigen-specific HLA-A2-specific
CD28 CAR-Tregs were superior to non-targeted CAR-Tregs
at preventing xenogeneic Graft vs. Host disease (GvHD) (50).
We used a CAR specific for HLA-A2 that did not have an
endodomain signaling component (1CAR) but still contained
the targeting domain (i.e., ScFV specific for HLA-A2) and
showed that although they were less efficient compared to fully
functional CD28 CAR-Tregs in vitro, in a humanized mouse
model of human skin transplant, 1CAR-Tregs offered greater
graft protection than polyclonal Tregs but less than CD28 CAR-
Tregs. We concluded that CAR-Treg localization and activation
via the TCR are important feature for their immunosuppressive
capacity (51). Similarly, Noyan et al. showed that HLA-A2
specific CD28 CAR-Tregs prevented skin allograft rejection in a
human skin transplant mouse model (52).
However, other co-stimulatory molecules expressed by Tregs
could potentially enhance their function, stability (avoiding
conversion to effector cells) and survival. To this end, Boroughs
et al. performed a side-by-side comparison of CAR-Tregs
expressing CARs encoding CD28 or 4-1BB endodomains. They
found that CAR-Tregs with the CD28 endodomain maintained
their inhibitory function whereas CAR-Tregs with the 4-1BB
endodomain did not. Furthermore, only CD28 CAR-Tregs and
not 4-1BB CAR-Tregs were effective suppressors of T-effector
cells in vivo and were the most effective at inhibiting EGFR-CAR
Teff mediated damage on EGFR+ skin transplant (90). This is
in contrast with what has been published with CAR-T cells, in
which the 4-1BB endodomain but not the CD28 endodomain
reduced CAR-T cell exhaustion resulting in enhanced CAR-
T cell persistence and longevity (57, 91). Despite several
recent successes, the overall understanding of the mechanisms
governing Treg stimulation remains somewhat limited.While the
evidence base is rapidly increasing, more work will be required to
gain insight into these precise mechanisms to generate optimized
potent and long-term stable therapeutic Tregs.
ENGINEERING BEYOND THE CAR
Enhancing the Safety Profile of CAR-Tregs
In clinical trials patient safety is of the highest priority. With
cellular therapy at the clinical trial phase it is not certain
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FIGURE 1 | Alternatives to CAR monospecificity. (A) Pooled antigen specific CARs against two different antigens. CAR1 targeting Antigen 1 (Ag1), displaying an
anti-Ag1 scFV, a CD28 extracellular region, a CD28 transmembrane domain, a CD28 signaling domain and a CD3ζ signaling domain, CAR2 targeting antigen 2 (Ag 2),
with anti-Ag2 scFv. (B) Dual CAR—two different CARS connecting molecule to interact with the cell of interest. (C) Bi-specific or Tandem CAR—CAR able to interact
with two different antigens. (D) Uni-CAR—using a connecting molecule to interact with the cell of interest. The CAR is displaying an anti-connecting molecule ScFv
and the targeted cell has a receptor for the connecting molecule. Only approach tested with Tregs.
whether the therapeutic cells will reach their intended destination
within the patient’s body and thus off-target effects may occur
(92–94). In the context of CAR-Tregs, if it were to function
off-target it could ensue a situation in which the patient
experiences pan-immunosuppression which leads to a reduced
appropriate immune response against opportunistic infections
and possibly cancer development. One way to control the
life of these injected therapeutic cells in the patient is to
include a suicide gene feature within these genetically modified
therapeutic cells before injecting them back into the patient.
Suicide genes are like a “safety switch” that permits selective
death on expressing cells in the event of elevated toxicity by
administration of an activating soluble pharmaceutical agent
in the patient (92–94). Examples of suicide genes include
surface proteins such as RQR8 (93) and huEGFRt (92)
which can be recognized by monoclonal antibodies (mAbs).
A potential drawback of mAbs-mediated suicide genes is
that the concentrations required for efficient elimination may
not be easily achieved due to accessibility of the mAbs to
desired tissues.
Other suicide genes can be activated by small molecules
such as the herpes simplex virus thymidine kinase (HSV1-
tk) and inducible caspase 9 (iCasp9) systems (94). HSV1-
tk is a non-toxic enzymatic protein that converts pyrimidine
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and acycloguanosine nucleoside analogs for example ganciclovir
into phosphorylated compounds that are toxic metabolites that
presents as chain terminators and specifically kill transduced
cells. This technology is widely used for cancer therapy (95).
iCasp9 is a fusion of a modified human FK506 binding protein-
12 (FKBP12) with the catalytic domain of human caspase 9,
and its conditional dimerization allows for its activity. iCasp9
has low potential immunogenicity and its function upon
activation is specific to the transduced cells. Furthermore,
iCasp9 maintains function in T cells overexpressing anti-
apoptotic molecules (94). These properties could promote
the choice for iCasp9 as a safety feature element in CAR-
Tregs amongst other human T cell therapies. Di Stasi et al.
published a study which enrolled five patients who had
undergone stem-cell transplant for relapsed acute leukemia
and treated with iCasp9-expressing T cells. With a single
dose of the dimerising drug it eliminated more than 90% of
the iCasp9-expressing T cells (96). The iCasp9 safety switch
has been incorporated in second generation CAR-T cells
used in clinical trials targeting GD2 for cancer treatment
(NCT01822652, NCT02439788) (59). Another clinical trial using
fourth generation CAR-T cell therapy also employed the iCasp9
technology (NCT02992210) (59).
Overall, it could be envisioned that the ideal CAR-Treg
product would be armored with an array of efficient co-
stimulatory domains and suicide genes.
Reporters for Spatiotemporal in vivo
Tracking
The administration of live cell therapeutics including CAR-Tregs
raises several important questions pertaining to cell therapy
localization and relocalization over time, sites of activity and
overall fate of administered cells. The existence of adoptively
transferred cells can be demonstrated with highly sensitive
methods based on blood samples. Cytotoxic T-cells have been
shown by qPCR to be present years after administration
in some patients (97). Administered Tregs have also been
demonstrated to be present for a long time in the circulation
of patients using a stable isotope labeling approach based
on deuterium; polyclonal Tregs labeled with [6,6-2H2]glucose
were detected in the circulation of Type I diabetes patients
for up to 1 year (14). Importantly, these methodologies
suffer from not providing answers to questions relating to
spatial localization, activity, and fate of the therapeutic cells
at target sites. Non-invasive whole-body imaging would be
a highly beneficial tool to answer all these questions in a
spatiotemporal manner.
The field of in vivo cell tracking has re-gained newmomentum
through the development of adoptive cell therapies. The
various cell tracking methodologies including a variety
of experimental design considerations and caveats have
recently been comprehensively reviewed (98), also in the
context of tracking T cell therapies (99). Fundamentally,
cells require labeling to visualize them in vivo using
technologies with exquisite sensitivities. Non-invasive
radionuclide imaging by single photon emission computed
tomography (SPECT) or positron emission tomography
(PET) offers excellent sensitivity with absolute quantification
and true 3D information while being translatable to
the clinic. Labels can be introduced into cells via two
fundamentally different methodologies, direct and indirect
cell labeling (98).
So-called “direct cell labeling” employs ready-to-use
contrast agents (e.g., organic fluorophores, quantum dots,
iron oxide nanoparticles, 19F-fluorinated contrast agents,
chelated radiometals etc.), which are introduced into cells either
due to the contrast agents being cell permeant, or through
assisted uptake (e.g., by transfection or internalization). We
previously showed that direct radiolabeling of polyclonal
murine CD4+ T cells with 99mTc-hexamethylpropyleneamine
oxime did not affect cell viability, but the radiolabeled cells
could only be tracked for up to 24 h due to the short half-
life of the radiolabel [half-life of 99mTc is 6.01h; (100)]. This
enabled the assessment of Treg biodistribution within a day
of administration but precluded long-term tracking of Tregs.
Longer half-life isotopes could provide this opportunity,
albeit are not free of caveats. The SPECT isotope 111In has
been used clinically to follow directly labeled white blood
cells for decades (101), but due to its decay properties it
has also been associated with significant radiodamage (102).
89Zr has a similar half-life as 111In and was used to track
cells for up to 2 weeks (103, 104). With clinical PET being
more sensitive than SPECT, not least through the very recent
development of total-body PET, which has been shown to be
another 40-times more sensitive than conventional PET (105),
89Zr-labeling would result in the use of less radioactivity to
achieve the same tracking results. However, radio-damage as
a consequence of radioisotope incorporation into cells must
be assessed, particularly in cell types such as T cells that are
routinely ablated using radiation. Therefore, careful dosimetry
considerations are required to assess both the preclinical and
clinical feasibility of Treg tracking via this route [for caveats
see (98)].
The alternative is “indirect cell labeling,” whereby a genetically
encoded reporter is ectopically introduced into the cells mostly by
viral transduction to ensure genomic integration and thus stable
long-term expression; transposon and gene editing represent
alternative methodologies (106, 107). Reporter genes have critical
advantages over direct labeling for cell tracking (99, 108). First,
the observation period is independent of the contrast agent, for
example, not affected by the half-life of a radioisotope. Second,
genetic encoding avoids label dilution phenomena, which are
limiting observation times in the case of fast-growing cells
(e.g., expanding T cells). Third, genetic encoding circumvents
complex direct cell labeling procedures and potential associated
cell toxicities. A drawback of the indirect cell labeling approach
is that it requires genetic engineering. However, this is not
a concern for preclinical experimentation and not a concern
for adoptive cell therapies that require genetic engineering to
confer targeting specificity and/or efficacy, such as CAR-Treg
therapy. Treg in vivo dynamics has been assessed preclinically
using bioluminescence reporters (109, 110). Dawson et al.
tracked HLA-A2 CAR-Tregs in vivo using bioluminescence and
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found that the peak of CAR-Treg infiltration to A2+ skin
graft was 7 days post infusion (53). However, this imaging
modality is not clinically translatable because of the non-
human nature of luciferases, and the added disadvantages
of optical imaging at depth (absorption, scatter) precluding
reliable quantification. As foreign reporters can elicit an immune
response and result in immune destruction of the administered
therapeutic cells, a host-compatible reporter is preferable in
this context. Host reporters are from the same species but
endogenously expressed in only a very limited number of host
tissues, and ideally at low levels to ensure favorable contrast
(99). The most promising host reporters available for the
purpose of Treg tracking in skin transplant models are the
human sodium iodide symporter (NIS) (111) and the human
prostate-specific membrane antigen (PSMA) (112), as neither
of them is expressed in human or mouse dermis or epidermis.
NIS offers the advantage of a generator-produced radiotracer
([99mTc]TcO−4 ) for SPECT imaging avoiding complex synthesis
on each imaging day. Notably, there is also a clinical PET
tracer available for NIS ([18F]BF−4 ), which is accessible via an
automated synthesis protocol (113, 114). Notably, Volpe et al.
have also demonstrated that NIS expression and use for imaging
did not result in radiodamage-related negative effects in CAR-
T cells (115). In a proof-of-principle study employing retroviral
transduction methodology, we demonstrated ex vivo engineering
of murine Tregs to express a radionuclide imaging reporter
and detected them 24 h post administration by SPECT imaging
(116). However, so far long-term tracking of human Tregs
has not been addressed using clinically translatable imaging
technologies and remains an important area of future research
to aid the development and clinical translation of adoptive
Treg therapy.
TRANSLATING CAR-TREGS TO THE
CLINIC
The quick evolution of CAR-T cells into clinic has informed
the scientific community of the pitfalls and hurdles associated
with delivering an effective, safe and reproducible treatment;
applying the lessons to CAR-Treg therapy should accelerate
their use in clinic. Fritsche et al. extensively reviewed optimized
methods in manufacturing GMP-grade CAR-Tregs (117) but
factors including generating “off-the-shelf ” products, increasing
in vivo persistence and eliminating CAR-associated toxicities are
a few examples of hurdles to overcome and will be discussed next.
Developing next-generation, or “off-the-shelf,” products is a
focal point for clinical translation of CAR-T cells and, equally,
must be considered for CAR-Treg therapy. Currently, the
manufacturing process of autologous CAR-T cells for cancer
patients incur a few paramount disadvantages, such as possible
failure during manufacturing, and critically, the 3 week long
process of developing the treatment which is a setback in highly
proliferative malignancies [reviewed in (118)]. Time critical
treatment delivery is not as big of a concern for CAR-Tregs in
autoimmunity and solid organ transplant rejection. However,
risk of failure due to low absolute numbers or functionally
defective Tregs because of the disease, or interference from
adjunct immunosuppressive medications need to be considered.
Most importantly, the high cost incurred of manufacturing and
delivery patient derived CAR-T cells has been a challenge for
health care systems and needs to be considered if CAR-Treg
therapy is to be translated into clinic. Previously, allogeneic CAR-
T cells generated from “healthy donors” have been considered as a
fast, scaled-up and decreased cost method of which high numbers
of CAR-T cells can be produced per donor, with the added
advantage of cryopreserving large batches, ready for treatment
immediately. However, this gave rise to GvHD or clearance by
the host’s immune system (119). Different strategies have looked
at generating manipulated “off the shelf ” CAR-T cell products.
The use of gene editing as a tool for generating off the shelf
CAR-T cells is very promising and can be translated to CAR-Treg
therapy. This can be achieved by using transcription-activator-
like effector nucleases (TALENs) to knock out the TCRα chain
(TRAC) or β2 microglobulin of the MHC molecule, to prevent
alloreactive T cells from inducing GvHD (120). CRISPR-Cas9 is
another tool to replace the TCRαβ with the CAR in the TRAC
locus or β2 microglobulin of the MHC molecule to minimize
immunogenicity avoiding GvHD (121, 122).
Concerns surrounding candidate patients who are on
immunosuppressive regiments may also interfere or crosstalk
with CAR-Treg efficacy. Drug such as antithymocyte globulin
(ATG), cyclosporin, anti-CD25 and rapamycin are administered
to transplant recipients and have an impact on Treg numbers
and function. ATG reduces the absolute number of Tregs
and high doses has been linked to impaired thymic Treg
development in allogeneic HSCT (123). Cyclosporin and other
calcineurin inhibitors (e.g., tacrolimus) suppress Treg activation
and decrease FOXP3 expression but this can be restored by
administration of IL-2 (124). We have shown in the ThRIL study
the efficacy of Treg therapy in patients on immunosuppressive
regimens including ATG and tacrolimus, which is encouraging
for future CAR-Treg trials (17). In contrast, drugs such as
sirolimus or everolimus, (rapamycin) inhibitors of the mTOR
pathway may have a beneficial effect as used in combination with
Tregs in the treatment of transplant patients as rapamycin is
routinely used in the ex vivo expansion of Tregs and promote
Tconv outgrowth (125).
CONCLUDING REMARKS
CAR-Tregs are the logical extension of polyclonal Treg therapy
to enhance their efficacy by conferring antigen-specificity. It is
an emerging area with not an insignificant amount of research
required to develop and adapt existing CAR-Treg concepts and
optimize them for successful clinical translation. As reviewed
here the application of CAR-Tregs to the clinic needs further
refinement. There is a need to maximize their suppressive
function, their stability and understand better their homing
capacity and longevity i.e., preventing CAR-Treg exhaustion.
Such cell products raise another concern and this is the cost
(126). Currently, treating a patient with anti-cancer CAR-
T cell therapy costs $400,000 without the ancillary costs
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(127). Furthermore, the critical rate needed to manufacture
personalized products, the failure to achieve the targeted cell
numbers in some patients, and the heterogeneity of the cell
products generated need to be overcome. However, the safety
demonstrated with the clinical application of polyclonal Tregs
and the pre-clinical data with CAR-Tregs has now generated
investment in CAR-Treg therapy and several start-up companies
have been funded, with the aim of applying CAR-Tregs to cure
autoimmune diseases and induce transplantation tolerance. The
first CAR-Treg clinical trial has been granted by UK MHRA
authorization in a phase I/II clinical trial (STEADFAST) for
kidney transplant patients. Progress in our understanding of
the biology of Tregs, the ability of functional enhancements
through genetic engineering, contribute to the excitement of this
field of research.
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GLOSSARY
Ab:mouse MHC Class II molecule.
Aurora B kinase: a protein involved in the cell cycle; it functions
in attaching the mitotic spindle to the centromere.
Bcl-2 (B-cell lymphoma 2): a protein, which regulates
programmed cell death; anti-apoptotic protein that functions
by preventing mitochondrial apoptogenic factors such as
cytochrome c and apoptosis-inducing factor (AIF) to be released
into the cytoplasm.
Bcl-xL (B-cell lymphoma-extra large): a protein that regulates
programmed cell death in a similar manner as Bcl-2.
GvHD (Graft-vs.-host disease): an immune condition that occurs
after transplant procedures when immune cells from the donor
(known as the graft or graft cells) attack the recipient patient
host’s tissues; the disease is a side effect that is common after an
allogeneic bone marrow transplant (stem cell transplant).
CRISPR/Cas9 (the clustered regularly interspaced short
palindromic repeats system): combines a nuclease and a short
RNA; specificity depends on RNA-DNA base pairing whereby
the RNA is complementary to the genomic target DNA. The
system most commonly uses Cas9, delivering the nuclease to the
target site.
HuEGFRt: a human epidermal growth factor receptor (EGFR)
polypeptide synthesized for cell selection by binding of an
anti-EGFR monoclonal antibody.
Human FK506 binding protein-12: a 12kD cytosolic protein
expressed ubiquitously; functions as a molecular chaperone for
protein folding.
Immunodysregulation polyendocrinopathy enteropathy
X-linked (also known as IPEX): a rare disease associated
with FOXP3 dysfunction, leading to Treg impairment and
severe autoimmunity.
PSMA (Prostate-specific membrane antigen): a protein
specifically expressed in prostate tissue carcinomas derived
from it.
RQR8: the protein product of a suicide gene; more speciofically,
a 136 amino acid construct, which enables selection with
the cliniMACS CD34 system and in vivo depletion of the
administered cells with rituximab.
Scurfy mouse: due to a mutation in the Foxp3 transcription
factor, Scurfy mice lack regulatory T-cells that maintain self-
tolerance of the immune system.
PET (Positron Emission Tomography): a radionuclide 3D
imaging modality used in the clinic; suitable radionuclides are
incorporated into radiopharmaceuticals, which are then used
to image specific biological process in vivo. The radioisotope
must be a positron emitter, whose emitted positrons combine
with electrons to produce two gamma rays pointing into
opposite directions; these gamma rays are detected by the
instrument and via reconstruction algorithms a 3D image
is formed.
SPECT (Single Photon Emission Computed Tomography):
a radionuclide 3D imaging modality used in the clinic;
radionuclides are incorporates into radiopharmaceuticals,
which are then used to image specific biological processes. The
radioisotope must be a suitable gamma ray emitter; gamma rays
pass through a collimator and are detected prior to econstruction
and 3D image formation.
Survivin: a protein that regulates apoptosis and the cell cycle; it
functions alongside aurora B kinase in facilitating completion of
the cell cycle. Survivin forms a chromosomal passenger complex
that regulates chromosome-microtubule attachment, proper
spindle assembly and occurrence.
TSDR (Treg-specific demethylated region): an evolutionarily
conserved element within the FOXP3 locus.
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